STAT

Opinion: NIH needs to raise the bar for funding alternative medicine research

The NIH needs a new way to review — and fund — alternative medicine grant proposals.
The National Center for Complementary and Integrative Health, part of the NIH, has supported studies such as "Long-Term Chamomile Therapy of Generalized Anxiety Disorder."

Suppose you needed to have a CT scan for a sudden, severe headache and partial loss of vision and your doctor asked a nutritionist to read it, rather than a radiologist. Would you trust the diagnosis? Evaluation by a different — and what most would consider a lesser — standard is essentially how a significant amount of research funding is approved by one component of the National Institutes of Health.

Let me step back for a minute before plunging ahead. Federally funded scientific research runs the gamut from studies of basic physical and biological processes to the. Government funding is especially essential for providing the scientific knowledge that underlies new medical treatments. The NIH, the nation’s major funder of nonmilitary research, has generally been a reliable supporter of high-quality research, conducted at its Bethesda, Md., campus and at universities and research institutes across the U.S.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related